Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 327Neoplasm Metastasis 31Advanced Breast Cancer 19Neoplasms 17Ovarian Neoplasms 11Hereditary Sensory and Autonomic Neuropathies 10Triple Negative Breast Neoplasms 8Prostatic Neoplasms 7Endometrial Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Breast Cancer Metastatic 6Uterine Cervical Neoplasms 5Breast Diseases 5Squamous Cell Carcinoma of Head and Neck 4Neoplasms by Site 4Colorectal Neoplasms 4Carcinoma, Ovarian Epithelial 4Small Cell Lung Carcinoma 3Recurrence 3Multiple Endocrine Neoplasia Type 1 3Head and Neck Neoplasms 3Breast Neoplasm Female 3Uterine Neoplasms 2Stomach Neoplasms 2Pancreatic Neoplasms 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Liposarcoma 2Hyperglycemia 2HER2-positive Metastatic Breast Cancer 2HER2-positive Breast Cancer 2

Interventions

abemaciclib 2Radiotherapy 2sargramostim 1ribociclib 1palbociclib 1niraparib 1exemestane 1Mastectomy, Segmental 1Mastectomy 1Letrozole 1Growth and Development 1Fulvestrant 1Everolimus 1Cyclophosphamide 1Continuous Positive Airway Pressure 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unilateral Breast Neoplasms × Fulvestrant × Breast × Clear all
NCT07062965 2026-05-06

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Pfizer

Phase 3 Recruiting
400 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡